PTGX · NASDAQ · STOCK
Protagonist Therapeutics, Inc.
$148.25
52W $53.49 – $151.88
65/100
$9.54B
121.7
1.79
Is PTGX Bullish or Bearish?
Bullish.
Innellis AI committee rates Protagonist Therapeutics, Inc. (PTGX) Buy with a composite score of 65/100
, based on 6 analysts with 67% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.72 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.28 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 15.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
65/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 17%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 115.4 is expensive by classic value standards
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 34.8% YoY -- genuine top-line momentum
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− Weekly RSI at 84 -- overbought on the larger timeframe too
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 15.4% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
63
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.17 across 6 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
68.1
Neutral
MACD Histogram
0.632
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.97
Inside Bands
Price vs Moving Averages
EMA 9
$142.93
Above
EMA 21
$137.97
Above
EMA 50
$128.10
Above
EMA 200
$101.76
Above
Fundamental Analysis
Valuation
33
Profitability
50
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
121.7×
P/B Ratio
11.62×
PEG Ratio
-0.14
Dividend Yield
0.00%
52W High
$151.88
52W Low
$53.49
Quality & Growth
ROE
-2117.2%
ROA
-1942.8%
Gross Margin
9985.6%
Operating Margin
2068.9%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 121.7 (rich relative to a 15-40x range); Price-to-book of 11.6x; PEG ratio of -0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -21.2%; Return on assets of -19.4%; Net margin of 29.4%; Gross margin of 99.9%; Current ratio of 21.71 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is positive (2.00); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full PTGX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →